Comparison of the effect of Neostigmine and Metoclopramide on gastric residual volume in mechanically ventilated ICU patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201412044365N18

Enrollment

Registered

2014-12-17

Start date

2013-02-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric residual volume. acute dilatation of stomach

Interventions

Intervention 1: Intrvention group 1: Neostigmine 2.5 mg in 100 ml normal saline infused during 30 minute at the beginning of trial. Intervention 2: Intrvention group 2: Metoclopramide 10 mg in 100 ml

Treatment - Drugs

Intrvention group 1: Neostigmine 2.5 mg in 100 ml normal saline infused during 30 minute at the beginning of trial.

Intrvention group 2: Metoclopramide 10 mg in 100 ml normal saline infused during 30 minute at the beginning of trial.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patient family agreement and informed written consent; under mechanical ventilation; nutrition via gastric tube; gastric residual volume greater than 120 cc; age between 20 and 70 years Exclusion criteria: diabetes; heart rate<60; heart blocks and arrhythmias; systolic BP less 90 mmHg; hypothermia (core temperature less 35); renal failure (Serum Creatinin more 1.5 in two consecutive test); prokinetic agents consumption during 8 hours before intervention; recent surgery on GI tract within 10 days; pregnancy and breast feeding; extrapyramidal sign; bronchospasm; hypokalemia (K less 3 meq/L); known sensitivity to Neostigmine and metoclopramide; GI bleeding

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Gastric residual volume. Timepoint: 0,3,6,9,12 hours after intervention. Method of measurement: Gastric lavage.	—

Secondary

Measure	Time frame
Albumin, Hemoglobin, WBC, Na, K, Mg. Timepoint: before trial. Method of measurement: laboratory kit.;Hear rate, blood pressure. Timepoint: during trial. Method of measurement: cardiac monitoring.;SOFA. Timepoint: before trial. Method of measurement: SOFA calculator.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Gholipour Baradari, MD

Mazandaran University of Medical Sciences

gholipourafshin@mazums.ac.ir; gholipourafshin@yahoo.com+98 11 3326 2679

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026